(Q39666339)

13 September 2017

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort (English)

1 reference

13 September 2017

Hospitalization Rates Differ by Hepatitis C Status in an Urban HIV Cohort (English)

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

17 March 2024

1 reference

1 reference

2

Marie Diener-West

1 reference

13 September 2017

1

Kelly A Gebo

1 reference

13 September 2017

Richard D. Moore

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14526205

17 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

13 September 2017

http://journals.lww.com/00126334-200310010-00006

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Journal of Acquired Immune Deficiency Syndromes

17 March 2024

published in

1 reference

13 September 2017

34

1 reference

13 September 2017

2

1 reference

13 September 2017

165-173

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

13 September 2017

1

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection

17 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine.

17 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA

17 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

17 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Hepatitis C virus infection in patients infected with the human immunodeficiency virus

17 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

17 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

17 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus.

17 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy

17 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

17 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

17 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus

17 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS).

17 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus

17 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Utilization of medical services by drug abusers in detoxification

17 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

The effects of immune status and race on health service use among people with HIV disease.

17 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Hospital and outpatient health services utilization among HIV-infected patients in care in 1999.

17 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Trends in HIV-related inpatient admissions from 1993 to 1997: a seven-state study.

17 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study

17 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis

17 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

17 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

17 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

17 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

17 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

The natural history of hepatitis C virus infection: host, viral, and environmental factors

17 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Correlates of hepatitis C virus infections among injection drug users.

17 March 2024

36

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.

17 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/00126334-200310010-00006

17 March 2024

Identifiers

1 reference

13 September 2017

1 reference